April 05, 2024
1 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
”
data-action=”subscribe”>
Subscribe
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].
Back to Healio
The FDA issued an emergency use authorization for CorDx TyFast Flu A/B & COVID-19 At Home Multiplex Rapid Test, according to an FDA roundup news release.
The test, manufactured by CorDx Inc., is for individuals displaying respiratory infection symptoms consistent with COVID-19 within the first 5 days of symptom onset. The single-use test is intended to detect and differentiate influenza A and B and SARS-CoV-2. According to the CorDx website, the 3-in-1 multiplex test is a lateral flow immunoassay device that provides a novel 10-minute diagnostic solution using samples collected via nasal swabs.
Samples can be self-collected by individuals aged 14 years and older, whereas those aged younger down to age 2 years should have nasal swab specimens collected by an adult, according to the FDA release.
The FDA’s decision to issue an emergency use authorization for the CorDx at-home test was based on validation data gathered through the NIH Independent Test Assessment Program, which was established as an FDA and NIH collaboration.
Published by:
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
”
data-action=”subscribe”>
Subscribe
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].
Back to Healio
